Last reviewed · How we verify

GCS Ramsay Santé pour l'Enseignement et la Recherche — Portfolio Competitive Intelligence Brief

GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Rachianesthesia Rachianesthesia marketed Other
standard pain relievers standard pain relievers marketed Nonsteroidal anti-inflammatory drug (NSAID) or analgesic COX-1 and/or COX-2 enzymes (for NSAIDs); central pain pathways (for acetaminophen) Pain Management
C1 Inhibitor Human C1 Inhibitor Human marketed Plasma-derived protease inhibitor C1 esterase inhibitor (C1-INH) Immunology / Rare Genetic Disorders

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for GCS Ramsay Santé pour l'Enseignement et la Recherche:

Cite this brief

Drug Landscape (2026). GCS Ramsay Santé pour l'Enseignement et la Recherche — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gcs-ramsay-sant-pour-l-enseignement-et-la-recherche. Accessed 2026-05-17.

Related